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Atherosclerosis in ApoE-deficient mice progresses
independently of the NLRP3 inflammasome
P Menu1,3, M Pellegrin2,3, J-F Aubert2, K Bouzourene2, A Tardivel1, L Mazzolai2,3 and J Tschopp*,1,3
The interleukin-1 (IL-1) family of cytokines has been implicated in the pathogenesis of atherosclerosis in previous studies.
The NLRP3 inflammasome has recently emerged as a pivotal regulator of IL-1bmaturation and secretion by macrophages. Little
is currently known about a possible role for the NLRP3 inflammasome in atherosclerosis progression in vivo. We generated
ApoE/ Nlrp3/, ApoE/ Asc/ and ApoE/ caspase-1/ double-deficient mice, fed them a high-fat diet for
11 weeks and subsequently assessed atherosclerosis progression and plaque phenotype. No differences in atherosclerosis
progression, infiltration of plaques by macrophages, nor plaque stability and phenotype across the genotypes studied were
found. Our results demonstrate that the NLRP3 inflammasome is not critically implicated in atherosclerosis progression in the
ApoE mouse model.
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Atherosclerosis is implicated in 50% of deaths in developed
countries, and is thus a major health issue. Although the precise
pathogenesis of the disease is complex and remains incomple-
tely understood, it is generally agreed that inflammation has
a pivotal role.1 In particular, the release of proinflammatory
cytokines by atherosclerotic plaque-infiltrating macrophages is
seen as critical. Interleukin-1b (IL-1b) is produced by activated
macrophages and considered a master switch of inflammation.
IL-1b and its related parent IL-1ahave both been implicated in the
pathogenesis of atherosclerosis in previous studies.2
Recent advances have shed light on the molecular
mechanisms governing the regulation of IL-1b maturation
and secretion by macrophages. NOD-like receptors (NLRs)
are a family of cytoplasmic pattern-recognition receptors that
have critical roles in innate immunity.3 In particular, some
NLRs have been shown to form caspase-1-activating cyto-
plasmic complexes called inflammasomes, responsible for
the processing of pro-IL-1b into its mature active form and its
subsequent secretion.4 The NLRP3 inflammasome is as-
sembled around the NLR scaffold protein NLRP3 upon
detection of pathogen-associated molecular patterns or
endogenous danger signals (danger-associated molecular
patterns). Upon activation, NLRP3 recruits the adapter protein
ASC, which in turn recruits procaspase-1.4 When brought into
close proximity, procaspase-1 molecules are able to transac-
tivate each other, resulting in the processing of pro-IL-1b.
The NLRP3 inflammasome has attracted considerable
attention because of its implication in several human diseases
and the availability of inhibitors of IL-1b that have been
recently very successful in clinical trials with patients suffering
from gout and type 2 diabetes.5 We therefore addressed the
issue of a possible role for the NLRP3 inflammasome in
atherosclerosis development.
Results
One of the reasons proposed to lead to the development of
atherosclerosis is the presence of oxidized low-density
lipoproteins (oxLDLs).6 Indeed, we found that cholesterol
oxidative derivatives such as 7-ketocholesterol, a major
component of oxLDL detectable in atherosclerotic plaques,6
induces secretion of the processed form of caspase-1 by
murine primary macrophages in an NLRP3 inflammasome-
dependent manner in vitro (Figure 1a).
The ApoE/mouse develops severe hypercholesterolemia
and spontaneous atherosclerosis, and is therefore a widely
accepted experimental mouse model to study atherosclerosis.7
Considering the capacity of 7-ketocholesterol to activate the
NLRP3 inflammasome, we next wanted to determine a possible
role of the NLRP3 inflammasome in atherosclerosis develop-
ment in vivo. To this end, we crossed Nlrp3/, Asc/ or
caspase-1/ mice with ApoE/ mice. Contrary to our
expectations, we found little differences between double knock-
outs and controls with respect to atherosclerotic plaque surface
across the aorta (Figure 1b) or the aortic valve (Figure 1b) of
these mice following 11 weeks on a high-fat diet. Cholesterol
crystals were similarly abundant in plaques of all mice.
Accordingly, plaque macrophage infiltration was equivalent in
all mice, as determined byMac-2 staining (Figure 2), suggesting
that NLRP3 inflammasome-deficient macrophages are equally
recruited in atherosclerotic plaques.
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In patients suffering from atherosclerosis, over 60% of
myocardial infarctions are caused by low-grade (o50%)
coronary artery stenosis.8 Therefore, the sheer surface of
atherosclerotic plaques is clinically less crucial than their stability.
Plaque smooth muscle cell content, a marker of plaque stability,
was quantified by anti-a-smoothmuscle actin staining (Figure 3).
Again, we found no significant differences between the four
genotypes. Furthermore, plaque phenotype was similar in all
mice, showing lesions in advanced stage (Table 1). Although
ApoE/ ASC/ mice featured significantly lower levels of
plaque layering and adventitial inflammation, this was offset by
an increased prevalence of thinned fibrous cap, suggesting that,
overall, the plaque phenotype was not decisively more or less
favorable than controls (Table 1).
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Figure 1 NLRP3 inflammasome deficiency does not impair atherosclerosis
progression in ApoE/ mice in vivo. (a) Lipopolysaccharide-primed murine bone
marrow-derived macrophages isolated from Nlrp3þ /þ and Nlrp3/ mice were
stimulated with 7-ketocholesterol and uric acid crystals (MSU, 150mg/ml) for 8 h as
indicated and analyzed by western blot. Active caspase-1 (mCasp1) released into
the supernatant (SN) was measured by western blot to determine NLRP3
inflammasome activation. (b) Oil Red O staining of thoracoabdominal aorta and
MOVATS staining of aortic valve plaques across the four indicated genotypes. Data
are shown as mean±S.E.M. The asterisk denotes Po0.05
Mac-2
Ap
oE
-/-
Ap
oE
-/-
 N
lrp
3-
/-
Ap
oE
-/-
 C
as
p1
-/-
Ap
oE
-/-
 A
SC
-/-
Mac-2
100
80
Ap
oE
-/-
Ap
oE
-/- 
Nlr
p3
-/-
Ap
oE
-/- 
Ca
sp1
-/-
Ap
oE
-/- 
AS
C-/
-
60
%
 M
ac
-2
 s
ta
in
in
g
40
20
0
Figure 2 Equal recruitment of macrophages to atherosclerotic plaques in
NLRP3 inflammasome-deficient ApoE/ mice. Plaque-infiltrating macrophages
were assessed with an anti-Mac-2 staining. Data are shown as mean±S.E.M.
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Figure 3 Plaque stability is unaltered in NLRP3 inflammasome-deficient
ApoE/ mice. Smooth muscle actin (SMA) staining of atherosclerotic plaques
across the four indicated genotypes
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Taken together, we conclude that NLRP3 inflammasome
deficiency does not affect atherosclerosis progression or
plaque phenotype in ApoE/ mice.
Discussion
Atherosclerosis is increasingly seen as a chronic inflam-
matory disease of the vessel wall. In this context,
plaque-infiltrating macrophages and the proinflammatory
cytokines that they secrete have critical roles. IL-1b is a
master switch of inflammation and has thus attracted
considerable attention regarding a putative role in the
pathogenesis of atherosclerosis.
In the present study, we show that the absence of the
NLRP3 inflammasome key components NLRP3, ASC or
caspase-1 does not influence atherosclerosis progression,
infiltration of plaques by macrophages, nor plaque stability in
an ApoE mouse model.
Our results are at odds with a recent report by Latz and
coworkers.9 Although our data agree that molecules report-
edly associated with atherosclerosis, such as cholesterol
crystals or oxidized lipids, can potently activate the NLRP3
inflammasome in vitro, our results concerning the involvement
of the NLRP3 inflammasome in atherosclerosis development
in vivo differ. Unlike in the present study, these authors used
mice deficient in the low-density lipoprotein receptor that
were transplanted with Nlrp3-, Asc- or IL-1a/b-deficient bone
marrow cells after lethal irradiation as a model of athero-
sclerosis. Compared with cells from wild-type mice, they
observed a 60% decrease in total lesion size at the aortic
sinus upon transfer of NLRP3-, ASC- or IL-1a/b-deficient cells,
and thus proposed an implication of the NLRP3 inflamma-
some in disease progression. Unfortunately, they did not
assess plaque quality or stability.
What could account for the divergence observed between
these two studies? One simple explanation may be the
difference in the mouse model used to study atherosclerosis.
Although both the ApoE/ and Ldlr/ mouse strains are
known to efficiently develop atherosclerotic lesions, some
notable differences exist. First, ApoE/ mice are generally
more hypercholesterolemic than Ldlr/ mice on a similar
high-fat diet; therefore, minor contributions of genes
possibly contributing to atherosclerosis might be missed in
the former model. Moreover, using the bone marrow
transplantation model, it is only possible to assess the
contribution of bone marrow-derived cells, but other cells
can also release active IL-1b and so other cellular sources of
IL-1b may influence disease progression. However, under
such a hypothesis, one would expect differences bet-
ween genotypes to be more pronounced in our double-
knockout mice.
Another explanation for the discrepancy could be that
mostly IL-1a and not IL-1b contributes to the pathogenesis of
atherosclerosis in ApoE/mice. Indeed, as active IL-1a can
be generated in the absence of the NLRP3 inflammasome via
a calpain-mediated processing,10 the absence of the NLRP3
inflammasome would not impair the progression of athero-
sclerosis. Moreover, IL-1a, like IL-1b, signals through the IL-1
receptor. This hypothesis is supported by several studies,
which primarily investigated the role of the IL-1R and its
naturally-occurring endogenous antagonist (IL-1Ra) in the
pathogenesis of atherosclerosis.2 IL-1R-deficient ApoE/
mice were shown to feature decreased atherosclerosis.11 In
accordance, genetically induced overexpression of IL-1Ra
(which blocks receptor access of both IL-1a and IL-1b) or
infusion of its recombinant form in ApoE/ mice resulted in
decreased atherosclerosis.12,13 Conversely, IL-1Ra-deficient
mice displayed enhanced atherosclerosis.14,15
IL-1a deficiency was reported to be associated with a 50%
decrease in atherosclerotic plaque area using a model of
C57BL/6 mice fed a high-fat diet.16 In that study, IL-1b
deficiency did not impair atherosclerosis progression in a
statistically significant manner. In another study, aortic sinus
lesion area in IL-1a-deficient ApoE/mice was lower than in
IL-1b-deficient ApoE/ mice.17
Taken together, our results suggest that atherogenesis in
ApoE/ mice can progress independently of the NLRP3
inflammasome, a complex that appears to be crucial in a
different mouse model of atherosclerosis. The most reason-
able explanations of the observed discrepancy between the
two studies lie in the different mouse models used, coupled to
a putative role of IL-1a in atherosclerosis development in the
ApoE mouse model. Clearly, further research is warranted
regarding the implication of inflammasomes and specific IL-1
family members in the pathogenesis of atherosclerosis.
Materials and Methods
Bone marrow-derived macrophages preparation, stimulation
and western blot. Primary murine macrophages were obtained from tibial
and femoral bone marrow cells as described elsewhere.18 Cells were primed
overnight with 100 ng/ml ultra-pure lipopolysaccharide (Invivogen, San Diego, CA,
USA), and stimulated the following day in OPTIMEM for 8 h. Uric acid and 7-
ketocholesterol were purchased from Sigma (Buchs, Switzerland). Cells extracts
and precipitated supernatants were analyzed by western blot. The antibody against
mouse caspase-1 (p20) is a generous gift from Dr. Peter Vandenabeele (Ghent
University).
Table 1 Plaque quality assessment in NLRP3 inflammasome-deficient ApoE/ mice
ApoE/ ApoE/ Nlrp3/ ApoE/ caspase-1/ ApoE/ Asc/
Advanced plaque staging 17/17 22/22 11/13 10/10
Media degeneration 17/17 22/22 13/13 10/10
Layering 16/17 22/22 10/13 4/10 (P¼0.0042)
Thinned fibrous cap 6/17 14/22 2/13 8/10 (P¼0.0461)
Large lipid core (450% of total plaque surface) 11/17 12/22 7/13 6/8
Adventitial inflammation 17/17 20/22 10/13 7/10 (P¼ 0.041)
The data represent the number ofmice presenting the characteristic over total number ofmice. Statistical analysis was carried out using Fisher’s exact test against the
control ApoE/ group in each case
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Mice and atherosclerosis progression determination. ApoE/
mice were from Jackson Laboratories (Bar Harbor, ME, USA; no. 002052);
Nlpr3/,19 ASC/20 and caspase-1/21 mice have been described. All mice
were on C57BL/6 background. ApoE/ mice were first crossed with Nlrp3/,
ASC/ or caspase-1/, and the resulting F1 mice were then backcrossed on the
ApoE/ background. F2 mice were then crossed again to obtain double-deficient
mice. The number of mice studied for each genotype was as follows: ApoE/,
n¼ 17; ApoE/ Nlrp3/, n¼ 18; ApoE/ caspase-1/, n¼ 13;
ApoE/ ASC/, n¼ 11. The 4-week-old mice were fed a high-fat diet
(KlibaNafag 3200 supplemented with 1.25% w/w cholesterol and 15% w/w cacao
butter; Kliba Nafag, Kaiseraugst, Switzerland) for 11 weeks and subsequently killed.
ApoE/ mice fed a high-fat diet were used as controls. Detailed procedures of
plaque surface, macrophage and smooth muscle cell quantification, as well as plaque
quality assessment are described elsewhere.22
Statistical analysis. Data are shown as mean±S.E.M. Statistical analysis
was carried out using a one-way analysis of variance coupled to a Dunnett post hoc
test, except for the assessment of plaque quality that relied on Fisher’s exact test.
Statistical significance was defined as Po0.05.
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